Tesamorelin vs Ipamorelin: GHRH vs GHRP Compared
Medically reviewed by Medical Advisory Board Last reviewed 2026-07-06
One is FDA-approved for visceral fat; the other is a clean GH pulse — they work on different receptors
Tesamorelin is a GHRH analog FDA-approved to reduce visceral (belly) fat in HIV-associated lipodystrophy; ipamorelin is a selective GHRP (ghrelin-receptor agonist) that triggers a clean growth-hormone pulse with minimal effect on cortisol or appetite. They act on different receptors, so they are often used together rather than as direct substitutes.
This article is for informational purposes only and is not medical advice. Peptide prescribing is tightly regulated — consult a licensed clinician.
Tesamorelin and ipamorelin are both growth-hormone secretagogues, but they belong to different classes and work on different receptors. Tesamorelin is a GHRH (growth hormone-releasing hormone) analog — it mimics the signal that tells the pituitary to release growth hormone. Ipamorelin is a GHRP (growth hormone-releasing peptide) that acts on the ghrelin receptor to trigger a separate GH pulse. Because they hit two different levers, they are frequently paired rather than chosen one-over-the-other. For the closely related comparisons, see tesamorelin vs sermorelin and ipamorelin vs sermorelin.
Want expert help with your metabolic health?
We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.
Book An Appointment With A Specialist →Tesamorelin vs Ipamorelin at a Glance
Tesamorelin and ipamorelin act on different receptors — GHRH versus the ghrelin receptor — which is why they are often combined rather than substituted. The table compares them on class, use, and evidence.| Dimension | Tesamorelin | Ipamorelin |
|---|---|---|
| Class | GHRH analog | GHRP (selective ghrelin agonist) |
| Receptor | GHRH receptor | Ghrelin (GHS) receptor |
| FDA status | Approved for HIV-associated visceral fat | Not FDA-approved; research/compounded use |
| Best known for | Reducing visceral (belly) fat | Clean GH pulse, minimal side effects |
| Cortisol / appetite effect | Minimal | Minimal (unlike GHRP-2/6 which raise appetite) |
| Half-life / dosing | Short; daily injection | Short; often dosed 1-3x daily |
| Often combined? | Yes — a GHRH + GHRP pair produces a larger, more synergistic GH release | |
Different Receptors, Different Jobs
The key to this comparison is that tesamorelin and ipamorelin are not competitors — they are complementary. Tesamorelin (a GHRH analog) amplifies the natural GHRH signal, and it's the only one of the two with FDA approval, specifically to reduce visceral fat in HIV-associated lipodystrophy. Ipamorelin (a GHRP) works through the separate ghrelin receptor to add a distinct GH pulse. Clinicians often combine a GHRH with a GHRP because the two pathways together produce a larger, more physiologic GH release than either alone. See GHRH vs GHRP for the underlying category difference.
Why Ipamorelin Is the 'Clean' GHRP
Ipamorelin earned its reputation as the cleanest GHRP because it triggers growth hormone release with minimal effect on cortisol, prolactin, or appetite — unlike older GHRPs such as GHRP-2 and GHRP-6, which noticeably increase hunger. That selectivity is why ipamorelin is often the GHRP of choice when the goal is a GH pulse without the side effects. It does not, however, carry tesamorelin's specific, trial-backed visceral-fat data.
Regulation and Access
Tesamorelin is FDA-approved (under the brand Egrifta) for a specific indication, so it has a clear regulatory pathway when prescribed for that use. Ipamorelin is not FDA-approved and is typically obtained through compounding pharmacies for research or off-label use, which places it in a grayer regulatory zone. Both should be sourced only through licensed clinical channels — products sold online for self-injection are unregulated. See our peptide therapy telehealth guide for how legitimate prescribing works.
The Bottom Line: Which Should You Consider?
These two peptides answer different questions:
- Targeting visceral (belly) fat with the strongest evidence: tesamorelin is the FDA-approved, trial-backed choice.
- Wanting a clean GH pulse with minimal side effects: ipamorelin is the selective GHRP built for exactly that.
- Maximizing GH release: a GHRH like tesamorelin combined with a GHRP like ipamorelin is often used together, not chosen apart.
Either way, growth-hormone peptides require clinical supervision and lab monitoring. Take the free assessment to review whether your goals point toward this peptide class or a different metabolic starting point.
Frequently Asked Questions
Is tesamorelin better than ipamorelin?
Neither is simply better — they do different jobs. Tesamorelin is a GHRH analog FDA-approved to reduce visceral fat, with trial data behind that use. Ipamorelin is a selective GHRP that triggers a clean growth-hormone pulse with minimal side effects. Because they act on different receptors, clinicians often combine them rather than pick one over the other.
Can you take tesamorelin and ipamorelin together?
Yes — combining a GHRH (tesamorelin) with a GHRP (ipamorelin) is a common approach because the two receptor pathways together produce a larger, more physiologic growth-hormone release than either alone. This should only be done under a licensed clinician's supervision with appropriate lab monitoring, not self-directed.
Which has fewer side effects, tesamorelin or ipamorelin?
Both are considered relatively clean compared with older GHRPs. Ipamorelin is specifically valued for triggering GH release without raising cortisol, prolactin, or appetite. Tesamorelin also has a favorable profile and, unlike ipamorelin, is FDA-approved with defined safety data for its indication. Individual tolerance varies and both need clinical monitoring.
Is ipamorelin FDA-approved like tesamorelin?
No. Tesamorelin is FDA-approved (brand Egrifta) to reduce visceral fat in HIV-associated lipodystrophy. Ipamorelin is not FDA-approved and is typically obtained through compounding pharmacies for research or off-label use. That regulatory difference matters — source either only through licensed clinical channels, never unregulated online sellers.
Topic updates
Get the weekly peptide roundup
Peptide therapy, GLP-1s, growth hormone peptides, healing peptides, safety notes, and comparison guides.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Comparisons
-
CJC-1295 + Ipamorelin Stack: Dosing Protocol, Timing & Results
CJC-1295 + ipamorelin stack: why they're synergistic, full dosing protocol, and results timeline.
-
Tesamorelin vs Sermorelin
Tesamorelin vs sermorelin: GH peptide differences, use cases, and which to choose.
-
Ipamorelin + HGH Fragment 176-191 Stack: Fat Loss Protocol and Dosing
Ipamorelin + HGH frag 176-191 stack for fat loss — dosing protocol and cycle guide.
See more related comparisons
-
Ipamorelin vs Sermorelin: GH Peptide Pathways, Dosing, and Which to Choose
Ipamorelin vs sermorelin: GHRP vs GHRH analog, mechanisms, dosing, and why they're stacked.
-
CJC-1295 vs Tesamorelin: FDA-approved GHRH Analog vs Longer-acting Unapproved Option
CJC-1295 vs tesamorelin: FDA-approved GHRH analog vs longer-acting unapproved option.
-
MK-677 vs Ipamorelin: Oral vs Injectable Growth Hormone Secretagogues
MK-677 vs ipamorelin: oral ghrelin agonist vs selective injectable GHRP.
-
AOD-9604 vs Tesamorelin: Which Fat-loss Peptide Has Real Evidence?
AOD-9604 vs tesamorelin: failed obesity trial vs FDA-approved visceral-fat peptide.
-
Ipamorelin: Growth Hormone Peptide Benefits, Dosage & Results
Ipamorelin for growth hormone release, body composition, and recovery.